Mixing and delivery of therapeutic compositions

Information

  • Patent Grant
  • 7883490
  • Patent Number
    7,883,490
  • Date Filed
    Wednesday, October 23, 2002
    22 years ago
  • Date Issued
    Tuesday, February 8, 2011
    13 years ago
Abstract
Syringe systems for mixing and delivery of particles into the body are disclosed. In some embodiments, a mixing and delivery medical syringe system can include a barrel including first and second detachable sections, and first and second compartments communicable through a conduit.
Description
TECHNICAL FIELD

This invention relates to mixing and delivery of therapeutic compositions.


BACKGROUND

Therapeutic vascular occlusions (embolizations) are induced by the introduction of various substances (embolic material, such as embolic particles) into a patient's circulatory system for the purpose of occluding vessels, either to arrest or to prevent hemorrhaging or to defunctionalize a structure or an organ. Typically, the components of an embolic composition-embolic particles in hydrating material (such as saline) and contrast agent (used for tracking the path of the embolic particles inside the body) are stored separately and mixed together at the time of injection into the body by the physician.


SUMMARY

In one aspect the invention features a mixing and delivery medical syringe system. The medical syringe system includes a barrel including first and second detachable sections, and first and second compartments communicable through a conduit.


In another aspect the invention feature a mixing and delivery medical syringe system. The medical syringe system includes a barrel having first and second compartments arranged in parallel along the barrel, the compartments communicable through a pressure-activated conduit.


In another aspect, the invention features a kit for medicant mixing and delivery, including a syringe system, which includes a barrel assembled from multiple sections, including a first section having a first chamber, and a second section having a second chamber. The syringe system includes a conduit between the first and second chambers through which flow can be controlled. The kit further includes a first container containing a first composition, and a second container containing a second composition.


In another aspect, the invention features a method for delivering injectable polymer particles by providing a syringe. The syringe includes a first compartment and a second compartment. A first component including injectable particles is loaded into at least one compartment, and the syringe is actuated to deliver the particles.


Embodiments can include one or more of the following. The conduit can include a pressure-activated separator. The separator can include a failure membrane. The failure membrane can include a weakened region. The weakened region preferentially effects rupture about a central region of the membrane. The weakened region preferentially affects rupture such that an attachment portion is not ruptured. The pressure-activated conduit can include a valve.


The first and the second compartments can be arranged serially along the syringe barrel. The barrel can include a vent valve. The barrel can include a fluid outlet and the outlet can include a valve. The first section can include the first chamber and the second section can include the second chamber. The conduit can be in one of the first or second sections.


The first composition can include injectable polymer particles. The particles can be embolic particles. The second composition can be a contrast agent. Alternatively, the second composition can include an anticancer agent.


The syringe can include a conduit between the compartments. A first component including injectable particles is loaded into at least one compartment and a second component is loaded into the second compartment. The first component and the second component are mixed in the syringe by flowing at least one of the components through the conduit. The second component can include a contrast agent. The second component can include a drug.


The method can include loading a second composition in the second compartment. The second composition can include polymer particles. The first component and second component can be delivered sequentially.


The first component and the second component can include polymer particles of different sizes or alternatively, of different shapes. The first component can include particles that are substantially spherical.


Embodiments may include one or more advantages. For example, pre-mixing the components may be undesirable because the shelf life of the mixed composition may be reduced for e.g., due to chemical interactions between a contrast agent and embolic particles.


The details of one or more embodiments of the invention are set forth in the accompanying drawings and the description below. Other features, aspects, and advantages of the invention will be apparent from the description and drawings, and from the claims.





DESCRIPTION OF DRAWINGS


FIG. 1A is a cross-sectional schematic of a syringe apparatus for mixing and delivery of a composition into the body.



FIG. 1B is an enlarged cross-sectional view showing a failure membrane of the syringe of FIG. 1A.



FIG. 1C is a top view of the failure membrane of the syringe of FIG. 1A.



FIG. 1D illustrates mixing of the components using the syringe of FIG. 1A.



FIG. 1E illustrates delivery of a mixture through a catheter using the syringe of FIG. 1A.



FIG. 2 is a schematic of a kit for mixing and delivery of a composition.



FIG. 3A is a cross-sectional schematic of a syringe apparatus for mixing and delivery of a composition into the body.



FIG. 3B is a top view of a failure membrane of the syringe of FIG. 3A.



FIGS. 3C and 3D illustrate mixing of the components of a composition using the syringe system of FIG. 3A.



FIG. 3E illustrates delivery of a mixture through a catheter using the syringe of FIG. 3A.



FIG. 4A is a cross-sectional schematic of a syringe apparatus for mixing and delivery of a composition into the body.



FIG. 4B illustrates mixing of the components of a composition using the syringe of FIG. 4A



FIG. 4C illustrates delivery of a composition through a catheter using the syringe of FIG. 4A.



FIG. 4D is a top view of a plunger lock of the syringe of FIG. 4A.



FIG. 5A is a cross-sectional schematic of a syringe apparatus for mixing and delivery of particles of different sizes.



FIG. 5B is a cross-sectional schematic of a syringe apparatus for mixing and delivery of particles of different shapes.





Like reference symbols in the various drawings indicate like elements.


DETAILED DESCRIPTION

Referring to FIG. 1A, a syringe apparatus 1 includes a body with an upper compartment 2, a lower compartment 3, a plunger 4 with a plunger base 11, a membrane 5, and a connector 9, which could be a luer connector, fitted with a stopcock 10. The lower compartment 3 contains a contrast agent 6 and the upper compartment 2 contains a combination of particles such as embolic particles 7 and a hydrating fluid such as saline 8. The upper compartment 2 and lower compartment 3 are fitted together at junction 19. The membrane 5 can be made of a polymer material or of cellulose based materials, such as cellulose acetate, that provides a liquid-tight seal between the upper and lower compartments so that the contrast agent may be isolated from interaction with the embolic material and saline mixture until the time of injection into the body.


Referring to FIGS. 1B and 1C, expanded views of the membrane 5 are illustrated. The membrane 5 has a failure region 13 and a hinge region 14. In one embodiment, the failure and hinge regions can be regions of reduced thickness. The thickness of the failure region 13 is less than the thickness of the hinge region 14 such that the membrane will fail preferentially at the failure region 13 and bend preferentially at the hinge region 14, in response to pressure increase in the upper compartment 2. Referring to FIG. 1C, a top view of the membrane 5 is illustrated showing the failure region 13 extending substantially around most of the circumference of the membrane, and the hinge region 14 extending along a short segment of the circumference. The reduced thickness regions of the membrane can be formed by heating, scoring or laser ablation.


Referring to FIG. 1D, with the stopcock 10 closed, pressure is applied in the upper compartment by depressing the plunger. The applied pressure on the failure membrane 5 causes it to rupture at the failure region 13 and to bend at the hinge region 14. The embolic particles and saline in the upper compartment 2 travel to the lower compartment 3 and mix with the contrast agent to form the mixed embolic composition 15. Because the embolic particles are initially located in the upper compartment and the contrast in the lower compartment, the particles fall into the contrast solution in a turbulent manner which enhances mixing and the creation of a uniform suspension of the particles in the mixture.


Referring to FIG. 1E, the stopcock 10 is opened to allow the mixed embolic composition 15 to pass via the connector 9, through a catheter 16 for injection into the body (not shown). The plunger can be further lowered to apply pressure for injecting the mixture into the body. In other embodiments, the stopcock 10 can be eliminated where the flow resistance of the syringe outlet and any attached delivery apparatus, such as a catheter, is sufficient to retard flow of solution in response to the pressure in the syringe after rupturing the membrane. The plunger base 11, particularly its circumference, may be made of a flexible rubbery material, such as an elastomeric polymeric material, that can deflect or bend when it engages the membrane so that the plunger can be lowered beyond the membrane into the lower compartment for injection of the mixture into the body.


Referring to FIG. 2, a syringe kit is illustrated. The kit includes a syringe barrel made of two detachable sections, 20 and 22, defining the upper compartment 2 and the lower compartment 3, a plunger 4 with a base 11, a vial 24 of embolic material 7 in saline 8, and a vial 26 of contrast agent 6. The upper section 20 of the syringe apparatus has a female-type connector 21 at its bottom end to fit with a male-type connector 23 at the top of the lower section 22. The connection between the upper and lower sections can be, for example, a pressfit, threaded or luer type connection. The lower section 22 has a connector 9 fitted with a stopcock 10. Failure membrane 5 can be placed between the upper and lower sections or can be preattached to one of the sections; in FIG. 2 the membrane is attached to the upper section. For use, the syringe apparatus is assembled as follows: Stopcock 10 is closed and contrast solution 6 from vial 26 is placed in the lower compartment 3 and the upper section is assembled with the lower section. Embolic material 7 along with saline solution 8 is placed in the upper compartment from vial 24. The plunger 4 is then placed in the upper compartment to complete the syringe assembly. The syringe can be provided commercially as a kit with the compartments preloaded with the appropriate components.


Referring to FIGS. 3A-3E, another embodiment of the syringe apparatus is illustrated. Here the failure membrane 30 is weakened across the center 31, as illustrated in FIG. 3B, for rupture on application of pressure. The rest of the syringe apparatus is as in the first embodiment illustrated in FIG. 1. Referring to FIG. 3C, the stopcock 10 is closed, and when pressure is applied to the upper compartment by depressing the plunger 4, the base 11 of the plunger conveys the applied pressure onto the failure membrane 30 causing its rupture at the weakened regions 31 (to form leaflets). The contents of the upper compartment 2 travel to the lower compartment 3 and mix with it to form the mixed embolic composition 15. Because the embolic particles are initially located in the upper compartment and the contrast in the lower compartment, the particles fall into the contrast solution in a turbulent manner which enhances mixing and the creation of a uniform suspension of the particles in the mixture. Referring to FIG. 3D, the plunger 4 is withdrawn, which causes the embolic composition 15 to backfill the upper compartment. This causes further mixing of the components of the embolic mixture and also prepares the apparatus for delivery of the embolic composition 15. Referring to FIG. 3E, stopcock 10 is opened and the plunger 4 is depressed to allow the embolic composition 15 to pass through the connector 9 to the catheter 16 for injection into the body (not shown). In other embodiments, the upper or lower compartments, or both upper and lower compartments can include a vent valve on the sidewall, (upper vent valve 33 shown in phantom in FIG. 3A) to enable pressure control within the syringe apparatus.


Referring to FIG. 4A, in another embodiment, a syringe barrel 40 is provided that has parallel compartments, including a left compartment 41 with a plunger 42, and a right compartment 43, with a plunger 44, both plungers 42 and 44 are fitted with a plunger lock 50. The plunger locks 50 prevent accidental deployment of the plungers. An expanded view of the plunger lock is illustrated in FIG. 4D. The plunger lock 50 includes a frame 54 consisting of a stationary vertical strip 56 placed towards one end of the frame and a movable vertical strip 57 placed towards the other end of the frame, with a threaded hole 58 at the center of the strip 57, through which a screw 59 is passed. The space between the two strips 56 and 57 houses the stem of the plunger. In use, to lock the plunger and prevent its deployment, the strip 57 is moved until the stem of the plunger is tightly held between strips 56 and 57. Counterclockwise movement of the screw 59 further secures the plunger tightly between the two strips 56 and 57. To unlock the plunger for deployment, the screw 59 is turned clockwise and the strip 57 is moved away from the plunger which loosens the grip of the two strips 57 and 58 on the stem of the plunger and unlocks the plunger for deployment. The plunger locks can be made of a metallic or polymeric material. To place the plunger lock 50 on the stem of the plunger, the plunger lock 50 is unlocked, the strip 57 is moved towards the frame, and the lock is slid onto the stem of the plunger from the top and is placed in any desired position on the stem of the plunger.


The compartments are divided by a central divider 45 with a pressure-activated two-way valve 46 at the end of the central divider 45, connecting the two compartments. The pressure-activated valve can include a polymer membrane 47 that can flex into either compartment based on the pressure differential between the compartments. A connector 48, at the bottom of the syringe assembly communicates with both compartments of the syringe and is fitted with a stopcock 49. The left compartment 41 contains the contrast solution 6, and the right compartment 43 contains a mixture of embolic particles 7 and saline solution 8.


Referring to FIG. 4B, the stopcock 49 is closed, the two plunger locks 50 on the left and right plungers 42 and 44 are unlocked, and the right plunger 44 is lowered causing the membrane 47 to flex into the left compartment and the valve 46 to open. Embolic particles and saline travel to the left compartment (arrow) and mix with the contrast solution to form the embolic mixture 15. Further thorough mixing may be achieved by repeated alternate operation of the two plungers, 42 and 44. Referring to FIG. 4C, the stopcock 49 is opened, the two plungers 42 and 44 are simultaneously depressed such that the embolic mixture 15 passes via the connector 48 through the catheter 16 for injection into the body (not shown). (Alternatively, the plungers can be depressed sequentially.) In other embodiments, the valve membrane can be a failure membrane.


Referring to FIG. 5A and FIG. 5B, another embodiment of the syringe apparatus is illustrated. In this embodiment, there is no two-way valve connecting the two compartments. The central divider 45 extends up to the connector 48 at the bottom of the syringe assembly. Referring to FIG. 5A, the left and right compartments 41 and 43 contain two different sizes of embolic particles, a smaller size 60, and a larger size 62, mixed with saline and/or contrast agent. Referring to FIG. 5B, the left and right compartments 41 and 43 contain two different shapes, a spherical shape 64, and an irregular shape 66, of embolic particles mixed with saline and or contrast agent. The rest of the syringe apparatus is as in the embodiment described in FIG. 4.


The arrangement allows delivery of two different sizes of embolic particles sequentially or simultaneously by sequential or simultaneous operation of the plungers. For example, smaller particles can be delivered first to travel to smaller diameter vessels, followed by larger particles to occlude vessels of larger diameter, upstream of the small diameter vessels. Alternatively, two different shapes of embolic particles can be delivered sequentially (or simultaneously). For example, spherical particles may be delivered first to aggregate and occlude distal regions and the irregular particles may be delivered second for more proximal aggregation.


In use, embolic particles in saline are disposed in the compartments from the top of the syringe, after removing the plungers. Contrast agent is drawn into each compartment from a supply in communication with the connector 48 by releasing the appropriate plunger lock and withdrawing the appropriate plunger. The syringe can be provided commercially as a kit with the compartments preloaded with the appropriate components. For injection into the body, the embolic composition with the desired embolic particle size and shape is injected into the body by release of the appropriate plunger lock, opening the stopcock 49, and depressing the appropriate plunger.


The mixing and delivery system discussed above can be used to deliver a number of compositions. Suitable embolic particles are polymer particles. Preferred particles are spherical particles formed of polyvinyl alcohol, as discussed in “Embolization”, U.S. Ser. No. 10/215,594, filed Aug. 9, 2002, the entire contents of which is incorporated herein by reference. A suitable contrast agent is Omnipaque 300 (Nycomed, Buckinghamshire, UK). (Omnipaque is an aqueous solution of iohexol, N.N.-Bis (2,3-dihydroxypropyl)-T-[N-(2,3-dihydroxypropyl)-acetamide]-2,4,6-trilodo-isophthalamide; Omnipaque 300 contains 647 mg of iohexol equivalent to 300 mg of organic iodine per ml). The syringe system can be used to premix and deliver other agents. For example, the systems can be used for mixing of drug agents, such as anti-cancer agents, with polymer particles as described in U.S. Ser. No. 10/232,265, filed Aug. 30, 2002. The system can be used to premix compositions without particles. A valve, such as in FIG. 4A can be used instead of the failure membrane in FIG. 1A. A membrane can be used that is not pressure-activated. For example, the membrane can be deflected by a control lever operable from outside of the syringe barrel. In another example, a sharpened member can be located on the plunger head that pierces the membrane.


Still further embodiments are in the following claims.

Claims
  • 1. A mixing and delivery medical syringe system, comprising: a syringe barrel including an upper compartment and a lower compartment;wherein the upper compartment and the lower compartment are detachably connectable to each other;a failure membrane disposed in the upper compartment;wherein the failure membrane is planar and includes: a first peripheral region having a first thickness,a second region connected to the first peripheral region, the second region having a second thickness less than the first thickness,a third region connected to the second region, the third region having a third thickness that is equal to the first thickness,a fourth region connected to the third region, the fourth region having a fourth thickness that is less than the first thickness and that is greater than the second thickness, anda fifth peripheral region connected to the fourth region, the fifth peripheral region having a fifth thickness that is equal to the first thickness;a vial of embolic material disposed in the upper compartment;a vial of contrast agent disposed in the lower compartment; anda plunger having a base.
  • 2. The system of claim 1, wherein the upper compartment has a female connector on a bottom end thereof.
  • 3. The system of claim 2, wherein the lower compartment has a male connector on a top end thereof, the male connector being configured to connect with the female connector.
  • 4. The system of claim 1, wherein the second region of the failure membrane is a failure region.
  • 5. The system of claim 1, wherein the fourth region of the failure membrane is a hinge region.
  • 6. The system of claim 5, wherein the failure membrane is circular and has a circumference, and wherein the hinge region extends along a short segment of the circumference of the failure membrane.
  • 7. The system of claim 1, wherein the failure membrane includes cellulose acetate.
  • 8. The system of claim 1, wherein the vial of embolic material includes saline.
  • 9. The system of claim 1, further comprising a stopcock attached to the lower compartment.
US Referenced Citations (354)
Number Name Date Kind
2275154 Merrill et al. Mar 1942 A
2609347 Wilson Sep 1952 A
3663470 Nishimura et al. May 1972 A
3737398 Yamaguchi Jun 1973 A
3957933 Egli et al. May 1976 A
4025686 Zion May 1977 A
4034759 Haerr Jul 1977 A
4055377 Erickson et al. Oct 1977 A
4076640 Forgensi et al. Feb 1978 A
4094848 Naito Jun 1978 A
4096230 Haerr Jun 1978 A
4098728 Rosenblatt Jul 1978 A
4110529 Stoy Aug 1978 A
4159719 Haerr Jul 1979 A
4191672 Salome et al. Mar 1980 A
4198318 Stowell et al. Apr 1980 A
4243794 White et al. Jan 1981 A
4246208 Dundas Jan 1981 A
4254768 Ty Mar 1981 A
4266030 Tschang et al. May 1981 A
4268495 Muxfeldt et al. May 1981 A
4271281 Kelley et al. Jun 1981 A
4402319 Handa et al. Sep 1983 A
4412836 Brignola Nov 1983 A
4413070 Rembaum Nov 1983 A
4427794 Lange et al. Jan 1984 A
4428869 Munteanu et al. Jan 1984 A
4429062 Pasztor et al. Jan 1984 A
4437858 Ty Mar 1984 A
4442843 Rasor et al. Apr 1984 A
4444961 Timm Apr 1984 A
4452773 Molday Jun 1984 A
4453934 Gahwiler et al. Jun 1984 A
4456693 Welsh Jun 1984 A
4459145 Elsholz Jul 1984 A
4472552 Blouin Sep 1984 A
4477255 Pasztor et al. Oct 1984 A
4492720 Mosier Jan 1985 A
4522953 Barby et al. Jun 1985 A
4542178 Zimmermann et al. Sep 1985 A
4551132 Pasztor et al. Nov 1985 A
4551436 Johnson et al. Nov 1985 A
4573967 Hargrove et al. Mar 1986 A
4597505 Mozley et al. Jul 1986 A
4622362 Rembaum Nov 1986 A
4623706 Timm et al. Nov 1986 A
4640807 Afghan et al. Feb 1987 A
4657756 Rasor et al. Apr 1987 A
4661137 Garnier et al. Apr 1987 A
4663358 Hyon et al. May 1987 A
4671954 Goldberg et al. Jun 1987 A
4674480 Lemelson Jun 1987 A
4675113 Graves et al. Jun 1987 A
4678710 Sakimoto et al. Jul 1987 A
4678814 Rembaum Jul 1987 A
4680320 Uku et al. Jul 1987 A
4681119 Rasor et al. Jul 1987 A
4695466 Morishita et al. Sep 1987 A
4713076 Draenert Dec 1987 A
4742086 Masamizu et al. May 1988 A
4743507 Franses et al. May 1988 A
4772635 Mitschker et al. Sep 1988 A
4782097 Jain et al. Nov 1988 A
4789501 Day et al. Dec 1988 A
4793980 Torobin Dec 1988 A
4795741 Leshchiner et al. Jan 1989 A
4801458 Hidaka et al. Jan 1989 A
4804366 Zdeb et al. Feb 1989 A
4819637 Dormandy, Jr. et al. Apr 1989 A
4822535 Ekman et al. Apr 1989 A
4833237 Kawamura et al. May 1989 A
4850978 Dudar et al. Jul 1989 A
4859711 Jain et al. Aug 1989 A
4863972 Itagaki et al. Sep 1989 A
4897255 Fritzberg et al. Jan 1990 A
4929400 Rembaum et al. May 1990 A
4933372 Feibush et al. Jun 1990 A
4935009 Caldwell et al. Jun 1990 A
4946899 Kennedy et al. Aug 1990 A
4954399 Tani et al. Sep 1990 A
4981625 Rhim et al. Jan 1991 A
4990340 Hidaka et al. Feb 1991 A
4999188 Solodovnik et al. Mar 1991 A
5007940 Berg Apr 1991 A
5011677 Day et al. Apr 1991 A
H0915 Gibbs May 1991 H
5015423 Eguchi et al. May 1991 A
5032117 Motta Jul 1991 A
5034324 Shinozaki et al. Jul 1991 A
5047438 Feibush et al. Sep 1991 A
5079274 Schneider et al. Jan 1992 A
5091205 Fan Feb 1992 A
5106903 Vanderhoff et al. Apr 1992 A
5114421 Polak May 1992 A
5116387 Berg May 1992 A
5120349 Stewart et al. Jun 1992 A
5125892 Drudik Jun 1992 A
5147631 Glajch et al. Sep 1992 A
5147937 Frazza et al. Sep 1992 A
5149543 Cohen et al. Sep 1992 A
5158573 Berg Oct 1992 A
5171214 Kolber et al. Dec 1992 A
5171217 March et al. Dec 1992 A
5181921 Makita et al. Jan 1993 A
5190760 Baker Mar 1993 A
5190766 Ishihara Mar 1993 A
5192301 Kamiya et al. Mar 1993 A
5202352 Okada et al. Apr 1993 A
5216096 Hattori et al. Jun 1993 A
5253991 Yokota et al. Oct 1993 A
5260002 Wang Nov 1993 A
5262176 Palmacci et al. Nov 1993 A
5263992 Guire Nov 1993 A
5288763 Li et al. Feb 1994 A
5292814 Bayer et al. Mar 1994 A
5302369 Day et al. Apr 1994 A
5314974 Ito et al. May 1994 A
5316774 Eury et al. May 1994 A
RE34640 Kennedy et al. Jun 1994 E
5320639 Rudnick Jun 1994 A
5328936 Leifholtz et al. Jul 1994 A
5336263 Ersek et al. Aug 1994 A
5344452 Lemperle Sep 1994 A
5344867 Morgan et al. Sep 1994 A
5354290 Gross Oct 1994 A
5369133 Ihm et al. Nov 1994 A
5369163 Chiou et al. Nov 1994 A
5382260 Dormandy, Jr. et al. Jan 1995 A
5384124 Courteille et al. Jan 1995 A
5397303 Sancoff et al. Mar 1995 A
5398851 Sancoff et al. Mar 1995 A
5403870 Gross Apr 1995 A
5409125 Kimber et al. Apr 1995 A
5417982 Modi May 1995 A
5431174 Knute Jul 1995 A
5435645 Faccioli et al. Jul 1995 A
5443495 Buscemi et al. Aug 1995 A
5445614 Haber et al. Aug 1995 A
5456693 Conston et al. Oct 1995 A
5468801 Antonelli et al. Nov 1995 A
5469854 Unger et al. Nov 1995 A
5476472 Dormandy, Jr. et al. Dec 1995 A
5484584 Wallace et al. Jan 1996 A
5490984 Freed Feb 1996 A
5494682 Cohen et al. Feb 1996 A
5494940 Unger et al. Feb 1996 A
5512604 Demopolis Apr 1996 A
5514090 Kriesel et al. May 1996 A
5525334 Ito et al. Jun 1996 A
5534589 Hager et al. Jul 1996 A
5541031 Yamashita et al. Jul 1996 A
5542935 Unger et al. Aug 1996 A
5553741 Sancoff et al. Sep 1996 A
5556391 Cercone et al. Sep 1996 A
5556610 Yan et al. Sep 1996 A
5558255 Sancoff et al. Sep 1996 A
5558822 Gitman et al. Sep 1996 A
5558856 Klaveness et al. Sep 1996 A
5559266 Klaveness et al. Sep 1996 A
5566729 Grabenkort et al. Oct 1996 A
5567415 Porter Oct 1996 A
5569193 Hofstetter et al. Oct 1996 A
5569449 Klaveness et al. Oct 1996 A
5569468 Modi Oct 1996 A
5571182 Ersek et al. Nov 1996 A
5580575 Unger et al. Dec 1996 A
5583162 Li et al. Dec 1996 A
5585112 Unger et al. Dec 1996 A
5595821 Hager et al. Jan 1997 A
5622657 Takada et al. Apr 1997 A
5624685 Takahashi et al. Apr 1997 A
5635215 Boschetti et al. Jun 1997 A
5637087 O'Neil et al. Jun 1997 A
5639710 Lo et al. Jun 1997 A
5648095 Illum et al. Jul 1997 A
5648100 Boschetti et al. Jul 1997 A
5650116 Thompson Jul 1997 A
5651990 Takada et al. Jul 1997 A
5653922 Li et al. Aug 1997 A
5657756 Vrba Aug 1997 A
5681576 Henry Oct 1997 A
5695480 Evans et al. Dec 1997 A
5695740 Porter Dec 1997 A
5698271 Liberti et al. Dec 1997 A
5701899 Porter Dec 1997 A
5704918 Higashikawa Jan 1998 A
5715824 Unger et al. Feb 1998 A
5716981 Hunter et al. Feb 1998 A
5718884 Klaveness et al. Feb 1998 A
5723269 Akagi et al. Mar 1998 A
5725534 Rasmussen Mar 1998 A
5733925 Kunz et al. Mar 1998 A
5741331 Pinchuk Apr 1998 A
5746734 Dormandy, Jr. et al. May 1998 A
5752974 Rhee et al. May 1998 A
5756127 Grisoni et al. May 1998 A
5760097 Li et al. Jun 1998 A
5766147 Sancoff et al. Jun 1998 A
5770222 Unger et al. Jun 1998 A
5779668 Grabenkort Jul 1998 A
5785642 Wallace et al. Jul 1998 A
5785682 Grabenkort Jul 1998 A
5792478 Lawin et al. Aug 1998 A
5795562 Klaveness et al. Aug 1998 A
5797953 Tekulve Aug 1998 A
5807323 Kriesel et al. Sep 1998 A
5813411 Van Bladel et al. Sep 1998 A
5823198 Jones et al. Oct 1998 A
5827502 Klaveness et al. Oct 1998 A
5827531 Morrison et al. Oct 1998 A
5830178 Jones et al. Nov 1998 A
5833361 Funk Nov 1998 A
5840387 Berlowitz-Tarrant et al. Nov 1998 A
5846518 Yan et al. Dec 1998 A
5853752 Unger et al. Dec 1998 A
5855615 Bley et al. Jan 1999 A
5863957 Li et al. Jan 1999 A
5876372 Grabenkort et al. Mar 1999 A
5877224 Brocchini et al. Mar 1999 A
5885216 Evans, III et al. Mar 1999 A
5885547 Gray Mar 1999 A
5888546 Ji et al. Mar 1999 A
5888930 Smith et al. Mar 1999 A
5891155 Irie Apr 1999 A
5894022 Ji et al. Apr 1999 A
5895398 Wensel et al. Apr 1999 A
5895411 Irie Apr 1999 A
5899877 Leibitzki et al. May 1999 A
5902832 Van Bladel et al. May 1999 A
5902834 Porrvik May 1999 A
5922025 Hubbard Jul 1999 A
5922304 Unger Jul 1999 A
5928626 Klaveness et al. Jul 1999 A
5935553 Unger et al. Aug 1999 A
5951160 Ronk Sep 1999 A
5957848 Sutton et al. Sep 1999 A
5959073 Schlameus et al. Sep 1999 A
6003566 Thibault et al. Dec 1999 A
6015546 Sutton et al. Jan 2000 A
6027472 Kriesel et al. Feb 2000 A
6028066 Unger Feb 2000 A
6047861 Vidal et al. Apr 2000 A
6048908 Kitagawa Apr 2000 A
6051247 Hench et al. Apr 2000 A
6056721 Shulze May 2000 A
6056844 Guiles et al. May 2000 A
6059766 Greff May 2000 A
6063068 Fowles et al. May 2000 A
6071495 Unger et al. Jun 2000 A
6071497 Steiner et al. Jun 2000 A
6073759 Lamborne et al. Jun 2000 A
6090925 Woiszwillo et al. Jul 2000 A
6096344 Liu et al. Aug 2000 A
6099064 Lund Aug 2000 A
6099864 Morrison et al. Aug 2000 A
6100306 Li et al. Aug 2000 A
6139963 Fujii et al. Oct 2000 A
6149623 Reynolds Nov 2000 A
6160084 Langer et al. Dec 2000 A
6162377 Ghosh et al. Dec 2000 A
6165193 Greene, Jr. et al. Dec 2000 A
6179817 Zhong Jan 2001 B1
6191193 Lee et al. Feb 2001 B1
6214331 Vanderhoff et al. Apr 2001 B1
6214384 Pallado et al. Apr 2001 B1
6224630 Bao et al. May 2001 B1
6224794 Amsden et al. May 2001 B1
6235224 Mathiowitz et al. May 2001 B1
6238403 Greene, Jr. et al. May 2001 B1
6245090 Gilson et al. Jun 2001 B1
6251661 Urabe et al. Jun 2001 B1
6258055 McCrory et al. Jul 2001 B1
6258338 Gray Jul 2001 B1
6261585 Sefton et al. Jul 2001 B1
6264861 Tavernier et al. Jul 2001 B1
6267154 Felicelli et al. Jul 2001 B1
6268053 Woiszwillo et al. Jul 2001 B1
6277392 Klein Aug 2001 B1
6280457 Wallace et al. Aug 2001 B1
6291605 Freeman et al. Sep 2001 B1
6296604 Garibaldi et al. Oct 2001 B1
6296622 Kurz et al. Oct 2001 B1
6296632 Luscher et al. Oct 2001 B1
6306418 Bley Oct 2001 B1
6306419 Vachon et al. Oct 2001 B1
6306425 Tice et al. Oct 2001 B1
6306427 Annonier et al. Oct 2001 B1
6312407 Zadno-Azizi et al. Nov 2001 B1
6312942 Plüss-Wenzinger et al. Nov 2001 B1
6315709 Garibaldi et al. Nov 2001 B1
6335384 Evans et al. Jan 2002 B1
6344182 Sutton et al. Feb 2002 B1
6355275 Klein Mar 2002 B1
6368658 Schwarz et al. Apr 2002 B1
6379373 Sawhney et al. Apr 2002 B1
6388043 Langer et al. May 2002 B1
6394965 Klein May 2002 B1
6423332 Huxel et al. Jul 2002 B1
6432437 Hubbard Aug 2002 B1
6436112 Wensel et al. Aug 2002 B2
6443941 Slepian et al. Sep 2002 B1
6458296 Heinzen et al. Oct 2002 B1
6476069 Krall et al. Nov 2002 B2
6495155 Tice et al. Dec 2002 B1
6544503 Vanderhoff et al. Apr 2003 B1
6544544 Hunter et al. Apr 2003 B2
6545097 Pinchuk et al. Apr 2003 B2
6575896 Silverman et al. Jun 2003 B2
6602261 Greene, Jr. et al. Aug 2003 B2
6602524 Batich et al. Aug 2003 B2
6605111 Bose et al. Aug 2003 B2
6629947 Sahatjian et al. Oct 2003 B1
6632531 Blankenship Oct 2003 B2
6652883 Goupil et al. Nov 2003 B2
6673050 Farris Jan 2004 B1
6676971 Goupil et al. Jan 2004 B2
6680046 Boschetti Jan 2004 B1
6692515 Boehm et al. Feb 2004 B2
6699222 Jones et al. Mar 2004 B1
6723067 Nielson Apr 2004 B2
6764463 Farris Jul 2004 B1
7131997 Bourne et al. Nov 2006 B2
7449236 Lanphere et al. Nov 2008 B2
7462366 Lanphere et al. Dec 2008 B2
7588780 Buiser et al. Sep 2009 B2
7611542 Bourne et al. Nov 2009 B2
20010001835 Greene, Jr. et al. May 2001 A1
20010016210 Mathiowitz et al. Aug 2001 A1
20010036451 Goupil et al. Nov 2001 A1
20010051670 Goupil et al. Dec 2001 A1
20020054912 Kim et al. May 2002 A1
20020061954 Davis et al. May 2002 A1
20020111580 Richeal et al. Aug 2002 A1
20020160109 Yeo et al. Oct 2002 A1
20020182190 Naimark et al. Dec 2002 A1
20020197208 Ruys et al. Dec 2002 A1
20030007928 Gray Jan 2003 A1
20030032935 Damiano et al. Feb 2003 A1
20030108614 Volkonsky et al. Jun 2003 A1
20030183962 Buiser et al. Oct 2003 A1
20030185895 Lanphere et al. Oct 2003 A1
20030185896 Buiser et al. Oct 2003 A1
20030187320 Freyman Oct 2003 A1
20030194390 Krall et al. Oct 2003 A1
20030203985 Baldwin et al. Oct 2003 A1
20030206864 Mangin Nov 2003 A1
20030215519 Schwarz et al. Nov 2003 A1
20030233150 Bourne et al. Dec 2003 A1
20040076582 DiMatteo et al. Apr 2004 A1
20040096662 Lanphere et al. May 2004 A1
20040101564 Rioux et al. May 2004 A1
20040186377 Zhong et al. Sep 2004 A1
20050025800 Tan Feb 2005 A1
20050037047 Song Feb 2005 A1
Foreign Referenced Citations (85)
Number Date Country
A-7618698 Oct 1998 AU
3 834 705 Apr 1990 DE
9414868.6 Feb 1995 DE
297 24 255 Oct 2000 DE
100 26 620 Mar 2002 DE
0 067 459 Dec 1982 EP
0112574 Dec 1983 EP
0 122 624 Oct 1984 EP
0 123 235 Oct 1984 EP
0 243 165 Oct 1987 EP
0 294 206 Dec 1988 EP
0 402 031 Dec 1990 EP
0 422 258 Apr 1991 EP
0 458 079 Nov 1991 EP
0 458 745 Nov 1991 EP
0 470 569 Feb 1992 EP
0 547 530 Jun 1993 EP
0 600 529 Jun 1994 EP
0 623 012 Nov 1994 EP
0 706 376 Apr 1996 EP
0 730 847 Sep 1996 EP
0 744 940 Dec 1996 EP
0 797 988 Oct 1997 EP
0 067 459 Mar 1998 EP
0 764 047 Aug 2003 EP
0 993 337 Apr 2004 EP
2 096 521 Mar 1997 ES
1099362 Sep 1955 FR
743789 Jan 1956 GB
1130593 Apr 1966 GB
59-196738 Nov 1984 JP
62-45637 Feb 1987 JP
4-74117 Mar 1992 JP
6-57012 Mar 1994 JP
9-110678 Apr 1997 JP
9-165328 Jun 1997 JP
9-316271 Dec 1997 JP
10-130329 May 1998 JP
2000189511 Jul 2000 JP
2001079011 Mar 2001 JP
2002 017848 Jan 2002 JP
255409 Feb 1997 NZ
517377 Aug 2003 NZ
421658 Feb 2001 TW
WO 9112823 May 1991 WO
WO 9221327 Dec 1992 WO
WO 9300063 Jan 1993 WO
WO 9319702 Oct 1993 WO
WO 9410936 May 1994 WO
WO 9503036 Feb 1995 WO
WO 9522318 Aug 1995 WO
WO 9533553 Dec 1995 WO
WO 9637165 Nov 1996 WO
WO 9639464 Dec 1996 WO
WO 9804616 Feb 1998 WO
WO 9810798 Mar 1998 WO
WO 9826737 Jun 1998 WO
WO9847532 Oct 1998 WO
WO 9900187 Jan 1999 WO
WO 9943380 Feb 1999 WO
WO 9912577 Mar 1999 WO
WO 9951278 Oct 1999 WO
WO 9957176 Nov 1999 WO
WO 0023054 Apr 2000 WO
WO 0032112 Jun 2000 WO
WO 0040259 Jul 2000 WO
WO 0071196 Nov 2000 WO
WO 0074633 Dec 2000 WO
WO 0112359 Feb 2001 WO
WO 0166016 Sep 2001 WO
WO 0170291 Sep 2001 WO
WO 0172281 Oct 2001 WO
WO 0176845 Oct 2001 WO
WO 0193920 Dec 2001 WO
WO 0211696 Feb 2002 WO
WO 0234298 May 2002 WO
WO 0234299 May 2002 WO
WO 0234300 May 2002 WO
WO 0243580 Jun 2002 WO
WO 03016364 Feb 2003 WO
WO 03051451 Jun 2003 WO
WO03082359 Oct 2003 WO
WO 2004019999 Mar 2004 WO
WO 2004073688 Sep 2004 WO
WO 2004075989 Sep 2004 WO
Related Publications (1)
Number Date Country
20040092883 A1 May 2004 US